Cerus and German Red Cross collaborate in red blood cell system development

28 September 2008

Cerus Corporation (NASDAQ: CERS) and the German Red Cross in the Baden-Württemberg–Hessen region (DRK Frankfurt) have agreed to collaborate in the development of Cerus' Intercept blood system for red blood cells.

DRK Frankfurt will invest expertise and personnel in support of commercial system design, commercial system validation, and activities directed toward German regulatory approval. In return, the agreement provides for DRK Frankfurt to receive royalties on potential sales of the Intercept red blood cell system in Europe.

The collaboration will provide Cerus with direct access to DRK Frankfurt’s scientific and operational expertise in relevant areas. The contract commits resources from DRK Frankfurt to support the development of the commercial product and design of a system compatible with blood processing procedures in Europe.

Under the agreement, the two organizations will also work together on planning for Phase 3 and Phase 4 clinical trials of the red blood cell system in Europe.

“Cerus is pleased that the largest region of the German Red Cross is committed to developing the Intercept red blood cell system,” said Claes Glassell, president and CEO of Cerus Corporation. “This collaboration reflects DRK Frankfurt’s recognition of the importance of pathogen inactivation and the merits of the Intercept Blood System. The collaboration will help guide the development of the Intercept red blood cell system to meet the operational and validation requirements in large blood centres.”

The DRK Frankfurt collects and processes 1.2 million units of red blood cells annually and has a research group that has conducted translational research in transfusion medicine for many years.

To top